Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong growth in key areas like MIEBO and contact lenses, despite challenges in the generics sector. Raised guidance for 2025 and successful recall management indicate resilience. The Q&A session reinforces confidence with strategic plans and market opportunities, despite some guidance ambiguities. Overall, positive developments in innovation, market strategy, and shareholder returns suggest a favorable stock price movement in the short term.
Total company revenue $1.278 billion, reflecting year-over-year growth of 3%. Excluding the enVista recall, total company revenue grew by 6%. The enVista recall had a $29 million impact on the Surgical segment.
Vision Care revenue $753 million, increased by 6% year-over-year. Growth driven by consumer and contact lenses. LUMIFY grew by 27% ($61 million revenue), dry eye portfolio grew by 19% ($115 million revenue), ARTELAC grew by 34%, and Blink grew by 13%. Eye vitamins declined by 8% due to retailer destocking.
Contact lenses revenue Growth of 7% year-over-year. Daily SiHy franchise grew by 36%, ULTRA monthly franchise grew by 8%, and Biotrue grew by 2%. Regional growth: U.S. up 11%, EMEA up 11%, LatAm up 25%, Japan up 3%, and China up 7%.
Surgical segment revenue $216 million, increased by 1% year-over-year. Excluding the enVista recall, growth was 15%. Consumables grew by 10%, Implantables declined by 16%, and Equipment declined by 2%.
Pharma segment revenue $309 million, declined by 1% year-over-year. U.S. branded Rx business grew by 8%, driven by MIEBO ($63 million revenue, 50% year-over-year growth) and XIIDRA ($82 million revenue, 12% year-over-year prescription growth). U.S. Generics business declined by 29%.
Adjusted gross margin 60.6%, decreased by 130 basis points year-over-year due to the enVista recall, product mix, and currency.
Adjusted R&D investment $96 million, increased by 12% year-over-year.
Adjusted EBITDA $192 million, absorbing a $19 million impact from the enVista recall and an $18 million impact from the decline in the U.S. Generics business.
Adjusted cash flow from operations $86 million for the quarter.
Dry Eye Portfolio: Achieved $1 billion in revenue milestone, with 19% growth in Q2. Key products include ARTELAC (34% growth) and Blink (13% growth).
Contact Lenses: Revenue grew by 7% in Q2, with strong performance across key brands. Daily SiHy franchise grew by 36%, ULTRA monthly franchise by 8%, and Biotrue by 2%.
LUMIFY: Generated $61 million in revenue in Q2, growing by 27%.
MIEBO: Delivered $63 million in Q2 revenue, with 50% year-over-year growth.
XIIDRA: Generated $82 million in Q2 revenue, with 12% year-over-year prescription growth.
Geographic Expansion: Contact lens business saw growth in key markets: U.S. (11%), EMEA (11%), LatAm (25%), Japan (3%), and China (7%).
ARTELAC Global Reach: Available in over 40 countries, with plans for further expansion.
enVista Intraocular Lenses: Returned to full production after a recall, with adoption rates increasing among surgeons.
Operational Excellence: Achieved 3% constant currency revenue growth in Q2, which would have been 6% excluding the enVista recall.
Capital Structure: Refinanced $3.1 billion in debt, extending maturities to 2031 with minimal impact on interest expense.
Dry Eye Market Leadership: Established as a leader with a robust portfolio addressing all patient needs, supported by education campaigns and new preservative-free OTC options.
Pipeline Innovation: Focused on category disruption with multiple clinical studies initiated and new product launches planned, including premium lenses like LuxLife and enVista Beyond.
enVista Recall Impact: The enVista recall significantly impacted the company's Surgical segment, reducing revenue growth from a potential 15% to 1% in Q2. The recall also caused a one-time $19 million impact on adjusted EBITDA and a 50 basis point headwind on adjusted gross margin.
U.S. Generics Business Underperformance: The U.S. Generics business declined by 29% in Q2, negatively affecting the Pharmaceutical segment's revenue growth, which dropped from a potential 6% to -1%. This underperformance also contributed an $18 million impact on adjusted EBITDA.
Tariff Policy Uncertainty: The fluidity of tariff policies poses a potential risk to the company's financial performance, although current guidance assumes the impact will be offset.
Operational Challenges in Product Resupply: The company faces challenges in ramping up production and resupplying the market for enVista implants, which is critical for recapturing lost momentum and revenue.
Market Education and Awareness Gaps: A lack of education and awareness in the dry eye market could limit the growth potential of the company's dry eye portfolio, despite strong product performance.
Currency Fluctuations: Currency fluctuations have had mixed impacts, with Q2 experiencing a $21 million tailwind but overall nominal impact year-to-date. This remains a variable risk to financial performance.
Revenue Guidance: The company has raised its full-year revenue guidance from a range of $5 billion to $5.1 billion to a range of $5.05 billion to $5.15 billion, representing constant currency growth of approximately 5% to 7%, up from 4.5% to 6.5%. This guidance absorbs approximately 100 basis points from the one-time impact of the enVista recall.
Adjusted EBITDA Guidance: The adjusted EBITDA guidance has been raised from a range of $850 million to $900 million to a range of $860 million to $910 million. This includes approximately $10 million driven by business performance and disciplined cost management.
Adjusted Gross Margin: The company expects an adjusted gross margin of approximately 61.5% for the full year, absorbing an estimated one-time 50 basis points headwind from the enVista recall.
R&D Investments: Full-year investments in R&D are expected to be about 7.5% of revenue.
Interest Expense: Interest expense for the full year is expected to be approximately $375 million.
Adjusted Tax Rate: The adjusted tax rate for the full year is expected to be approximately 15%.
Capital Expenditures: Full-year capital expenditures are expected to be approximately $280 million.
Phasing Expectations: The fourth quarter is expected to be the highest in terms of revenue and adjusted EBITDA due to natural seasonality, the ramp-up of enVista, and actions to improve performance in the U.S. Generics business.
Tariff Impact: The updated guidance assumes the company will be able to offset the impact of tariffs in 2025 based on current policy and actions taken.
Dry Eye Portfolio Growth: The dry eye portfolio achieved 16% constant currency revenue growth in Q2, with plans for further expansion and education campaigns to address market gaps.
Contact Lens Portfolio Expansion: Plans to introduce multifocal and toric options in the daily SiHy portfolio in several markets next year, with expected benefits of offering a full suite of lenses.
Premium Surgical Offerings: Anticipated soft launch of enVista MV in Europe later this year and expected early 2027 U.S. launch for enVista Beyond.
Pipeline Development: Multiple clinical studies have been initiated for new products, with a focus on category disruption rather than modest improvement. Further details will be shared at the November Investor Day.
The selected topic was not discussed during the call.
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
The earnings call highlights strong growth in key areas like MIEBO and contact lenses, despite challenges in the generics sector. Raised guidance for 2025 and successful recall management indicate resilience. The Q&A session reinforces confidence with strategic plans and market opportunities, despite some guidance ambiguities. Overall, positive developments in innovation, market strategy, and shareholder returns suggest a favorable stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
